Daiichi Sankyo’s Vanflyta has become the first drug in the US to be approved for newly-diagnosed acute myeloid leukaemia (AML) with FLT3-ITD mutations, nearly four years after being rejected by ...
See the committee papers for full details of the evidence. For people who can have intensive chemotherapy, initial treatment for FLT3‑ITD‑positive AML is normally midostaurin with standard ...